<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229280</url>
  </required_header>
  <id_info>
    <org_study_id>BDBEQ_DFNLP/ELEA_010</org_study_id>
    <nct_id>NCT01229280</nct_id>
  </id_info>
  <brief_title>Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.</brief_title>
  <official_title>Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Clinical Pharmacology Research Bdbeq S.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorio Elea Phoenix S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Clinical Pharmacology Research Bdbeq S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study was designed as a randomized two-sequence, two period crossover trial to&#xD;
      assess the bioequivalence, pharmacokinetic profiling and safety of a brand generic&#xD;
      formulation of darifenacin [Darisec(R) 7.5 mg] vs. the innovator [Enablex(R)7.5 mg]in healthy&#xD;
      volunteers in postprandial state.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Darifenacin is a muscarinic receptor antagonist drug used to treat overactive bladder. There&#xD;
      is a new formulation of darifenacin extended release developed by an argentinian&#xD;
      pharmaceutical company. A bioequivalence study will be performed to validate pharmaceutical&#xD;
      development before introducing the product in the market.&#xD;
&#xD;
      The purpose in this study is to evaluate the relative bioavailability, pharmacokinetic&#xD;
      profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7.5 mg] vs.&#xD;
      the innovator [Enablex(R) 7.5 mg]in 24 healthy uruguayan volunteers after a high fat&#xD;
      breakfast of 1000 calories (50% fat, 35% carbohydrates, and 15% proteins)to establish their&#xD;
      average bioequivalence.&#xD;
&#xD;
      The bioequivalence will be evaluated using:&#xD;
&#xD;
        -  The Area Under the Curve (AUC),&#xD;
&#xD;
        -  The peak plasma concentration (Cmax).&#xD;
&#xD;
      The pharmacokinetic characteristics of the drug formulations will be described calculating:&#xD;
&#xD;
        -  The time to peak concentration (Tmax)&#xD;
&#xD;
        -  The elimination constant (Ke)&#xD;
&#xD;
        -  The elimination half-life (t1/2e)&#xD;
&#xD;
        -  The systemic clearance (Cls)&#xD;
&#xD;
      Safety will be evaluated recording:&#xD;
&#xD;
        -  Reported adverse events&#xD;
&#xD;
        -  Vital signs (blood pressure, heart rate, body temperature)&#xD;
&#xD;
        -  Laboratory analysis (hemogram, hepatic enzymes, creatinine, sugar in blood, etc.)&#xD;
&#xD;
        -  EKG and chest XRays&#xD;
&#xD;
      Bioequivalence will be claimed if the drugs comply with local and FDA regulatory&#xD;
      requirements:&#xD;
&#xD;
        -  Mean AUCt/AUCr and 90% confidence interval within 0.80-1.25&#xD;
&#xD;
        -  Mean Cmaxt/Cmaxr and 90% confidence interval within 0.80-1.25&#xD;
&#xD;
      Pharmacokinetic profiling will be evaluated by describing the pharmacokinetic characteristics&#xD;
      of both drug in adequate two-way tables.&#xD;
&#xD;
      Safety will be evaluated comparing incidence of adverse events/adverse effects for both&#xD;
      products.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of absorption</measure>
    <time_frame>72 hours</time_frame>
    <description>Extent of absorption will be measured using the area under the plasma concentration of darifenacin vs time from time 0 to the last sample point (AUC0-t) and from time 0 to infinity (AUC0-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of absorption</measure>
    <time_frame>72</time_frame>
    <description>Rate of abosorption will be measured using peak concentration of darifenacin (Cmax)taken from the concentration vs. time curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to peak concentration (tmax)</measure>
    <time_frame>72</time_frame>
    <description>Tmax is the time elapsed from ingestion of darifenacin tablets to plasma peak concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Ke)</measure>
    <time_frame>72 hours</time_frame>
    <description>The elimination rate constant is the fractional rate of drug disappearance form the peripheral compartement, measured in the log-linear elimination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (t1/2e)</measure>
    <time_frame>72 hours</time_frame>
    <description>t1/2e is the time in which the concentration in the log-linear elimination phase drops by half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (Cls)</measure>
    <time_frame>72 hours</time_frame>
    <description>Cls is the amount of plasma volume units that are totally cleared of the drug in the unit of time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Bioequivalency</condition>
  <arm_group>
    <arm_group_label>Darisec(R) 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enablex(R) 7.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>Single dose 7.5 mg tablets of darifenacin</description>
    <arm_group_label>Darisec(R) 7.5 mg</arm_group_label>
    <other_name>Muscarinic antagonist</other_name>
    <other_name>Cholinergic antagonist</other_name>
    <other_name>Cholinergic agent</other_name>
    <other_name>Darisec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin</intervention_name>
    <description>Single dose 7.5 mg tablets of Darifenacin</description>
    <arm_group_label>Enablex(R) 7.5 mg</arm_group_label>
    <other_name>Muscarinec antagonist</other_name>
    <other_name>Cholinergic antagonist</other_name>
    <other_name>Cholinergic agent</other_name>
    <other_name>Enablex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects 18 to 50 years of age (inclusive).&#xD;
&#xD;
          -  In good health, as determined by lack of clinically significant abnormalities at&#xD;
             screening as judged by the physician.&#xD;
&#xD;
          -  Female subjects are required to use a medically accepted method of hormonal&#xD;
             contraception or abstinence throughout the entire study period and for one week after&#xD;
             the study is completed.&#xD;
&#xD;
          -  Body mass index within the range of 18.5 and 29.9 kg/m2 and weight at least 45 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or severe adverse event to darifenacin or similar drugs.&#xD;
&#xD;
          -  Urinary, retention, narrow-angle glaucoma, myasthenia gravis, severe hepatic&#xD;
             impairment, severe ulcerative colitis, toxic megacolon.&#xD;
&#xD;
          -  Symptomatic hiatus hernia, erosive or symptomatic gastroesophageal reflux&#xD;
             disease/heartburn (&gt;2 days in a week), severe constipation, gastrointestinal&#xD;
             obstructive disorder, and gastric retention.&#xD;
&#xD;
          -  Clinically significant cardiac abnormalities, fainting, low blood pressure upon&#xD;
             standing, irregular heartbeats.&#xD;
&#xD;
          -  Acute or chronic bronchospastic disease(including asthma and Chronic Obstructive&#xD;
             Pulmonary Disease).&#xD;
&#xD;
          -  Clinically significant drug allergy or history of atopic allergy (asthma, urticaria,&#xD;
             eczematous dermatitis).&#xD;
&#xD;
          -  Smokers of more than 5 cigarettes a week.&#xD;
&#xD;
          -  Regular use of any drug known to induce or inhibit hepatic drug metabolism&#xD;
             (particularly those that affect CYP2D6) within 30 days prior to each study drug&#xD;
             administration.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs which may jeopardize participation in&#xD;
             the study.&#xD;
&#xD;
          -  Immunodeficiency diseases, including a positive HIV (Elisa or Western blot) test&#xD;
             result.&#xD;
&#xD;
          -  Positive Hepatitis B Surface antigen (HBsAg) or Hepatitis C results.&#xD;
&#xD;
          -  Drug or alcohol abuse within the 6 months prior to dosing.&#xD;
&#xD;
          -  Use of prescription drugs within 1 month prior to dosing, or over-the-counter&#xD;
             medication (vitamins, herbal supplements, dietary supplements)within 2 weeks prior to&#xD;
             dosing. Paracetamol and ibuprofen are acceptable.&#xD;
&#xD;
          -  Participation in any clinical investigation within 12 weeks prior to dosing.&#xD;
&#xD;
          -  Donation or loss of 400 ml or more of blood within 8 weeks prior to dosing.&#xD;
&#xD;
          -  Significant illness within 2 weeks prior to dosing.&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco E. Estevez-Carrizo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Univerisity of Montevideo. Biomedical Science Center.Prudencio de Pena 2440, 11600 Montevideo. Uruguay</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susana Parrillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Pharmacology Research Bdbeq S.A., Br. Artigas 1632. c.p. 11600 Montevideo. Uruguay.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Santoro, MD</last_name>
    <phone>+541143794300</phone>
    <email>santorof@elea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Steimberg, MBA</last_name>
    <phone>+541143794330</phone>
    <email>steimbej@elea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano.</name>
      <address>
        <city>Montevideo</city>
        <zip>11600</zip>
        <country>Uruguay</country>
      </address>
    </facility>
    <contact>
      <last_name>Francisco E. Estevez-Carrizo, M.D.</last_name>
      <phone>+59824876288</phone>
      <email>francisco.estevez@bdbeq.com.uy</email>
    </contact>
    <contact_backup>
      <last_name>Mónica Cedrés, Pharm. B.</last_name>
      <phone>+59824876288</phone>
      <email>mcderes@bdbeq.com.uy</email>
    </contact_backup>
    <investigator>
      <last_name>Susana Parrillo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uruguay</country>
  </location_countries>
  <reference>
    <citation>Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. Review.</citation>
    <PMID>16584282</PMID>
  </reference>
  <reference>
    <citation>Croom KF, Keating GM. Darifenacin: in the treatment of overactive bladder. Drugs Aging. 2004;21(13):885-92; discussion 893-4. Review.</citation>
    <PMID>15493952</PMID>
  </reference>
  <reference>
    <citation>Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013-28. Review.</citation>
    <PMID>16363885</PMID>
  </reference>
  <reference>
    <citation>Kerbusch T, Wählby U, Milligan PA, Karlsson MO. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003 Dec;56(6):639-52.</citation>
    <PMID>14616424</PMID>
  </reference>
  <reference>
    <citation>Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology. 2000 Dec 4;56(6 Suppl 1):41-9. Review.</citation>
    <PMID>11114562</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Francisco E. Estevez-Carrizo</name_title>
    <organization>Center for Clinical Pharmacology Research Bdbeq S.A.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Darifenacin</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Postprandial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darifenacin</mesh_term>
    <mesh_term>Muscarinic Antagonists</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 10, 2012</submitted>
    <returned>November 7, 2012</returned>
    <submitted>December 14, 2012</submitted>
    <returned>January 23, 2013</returned>
    <submitted>March 22, 2013</submitted>
    <returned>May 1, 2013</returned>
    <submitted>June 30, 2014</submitted>
    <returned>July 30, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

